{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:44:09Z","timestamp":1782942249388,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcf.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:00:06Z","timestamp":1782446406000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SPL84 and Trikafta\u00ae exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C\u2192T\/F508del CFTR variants"],"prefix":"10.1016","author":[{"given":"Yi","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-8162","authenticated-orcid":false,"given":"Yifat S.","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3237-6737","authenticated-orcid":false,"given":"Jan","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Ozeri-Galai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava D.","family":"Stampfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Mordechai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-5309","authenticated-orcid":false,"given":"Ofra","family":"Barchad-Avitzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2653-8962","authenticated-orcid":false,"given":"Kevin","family":"Coote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-1548","authenticated-orcid":false,"given":"Hermann","family":"Bihler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-9789","authenticated-orcid":false,"given":"Martin","family":"Mense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-0379","authenticated-orcid":false,"given":"Batsheva","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.06.005_bib0001","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2024.10.004","article-title":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C-to-T","volume":"24","author":"Caraco","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0002","unstructured":"SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosisc https:\/\/www.prnewswire.com\/news-releases\/splisense-reports-positive-results-from-phase-2-study-of-spl84-in-cystic-fibrosis-302544977.html."},{"key":"10.1016\/j.jcf.2026.06.005_bib0003","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199410133311503","article-title":"A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations","volume":"331","author":"Highsmith","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcf.2026.06.005_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1513\/AnnalsATS.202006-659OC","article-title":"Ivacaftor in people with cystic fibrosis and a 3849+10kb C\u2192T or D1152H residual function mutation","volume":"18","author":"Kerem","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.06.005_bib0006","unstructured":"Trikafta label 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda.docs\/label\/2024\/212273s013lbl.pdf."},{"key":"10.1016\/j.jcf.2026.06.005_bib0007","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The french compassionate program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.005_bib0009","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jcf.2026.06.005_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcf.2026.06.005_bib0012","author":"Wexler"},{"key":"10.1016\/j.jcf.2026.06.005_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jcf.2026.06.005_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0015","article-title":"FDA Approves TRIKAFTATM (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del","year":"2019","journal-title":"Mutat"},{"key":"10.1016\/j.jcf.2026.06.005_bib0016","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0017","unstructured":"Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA Responsive Variants 2024. https:\/\/news.vrtx.com\/node\/33071\/pdf."},{"key":"10.1016\/j.jcf.2026.06.005_bib0018","unstructured":"Vertex Announces FDA Approvals of TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor\/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for Use in People With CF With Certain Rare Mutations 2020. https:\/\/investors.vrtx.com\/node\/27896\/pdf."},{"key":"10.1016\/j.jcf.2026.06.005_bib0019","unstructured":"European Commission Approves Expanded Label for KAFTRIO\u00ae in Combination With Ivacaftor for People With Cystic Fibrosis 2025. https:\/\/news.vrtx.com\/node\/33631\/pdf."},{"key":"10.1016\/j.jcf.2026.06.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.06.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-61779-117-8_4","article-title":"Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators","author":"Neuberger","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcf.2026.06.005_bib0022","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/bph.14141","article-title":"Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule","volume":"175","author":"Liu","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2026.06.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. food and drug administration\u2019s experience with ivacaftor in cystic fibrosis: Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.06.005_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0026","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2026.06.005_bib0027","unstructured":"Kia\u2019i N, Bajaj T. Histology, Respiratory Epithelium. 2025."},{"key":"10.1016\/j.jcf.2026.06.005_bib0028","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1021\/acsbiomaterials.2c01460","article-title":"Easy-to-build and reusable microfluidic device for the dynamic culture of human bronchial cystic fibrosis epithelia","volume":"9","author":"Mazio","year":"2023","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.jcf.2026.06.005_bib0029","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/rccm.201706-1139OC","article-title":"Mucin production and hydration responses to mucopurulent materials in normal versus cystic fibrosis airway epithelia","volume":"197","author":"Abdullah","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0030","unstructured":"Kalydeco lable https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203188s029,207925s008lbl.pdf."},{"key":"10.1016\/j.jcf.2026.06.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa490","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcf.2026.06.005_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0033","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/14656566.2023.2230129","article-title":"The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?","volume":"24","author":"Oliver","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jcf.2026.06.005_bib0034","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcf.2026.06.005_bib0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.06.005_bib0036","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: how much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0037","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0039","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S2213-2600(25)00190-0","article-title":"Sweat chloride and lung function responses to elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies","volume":"13","author":"Burgel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.06.005_bib0040","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bbadis.2007.10.004","article-title":"Coupling cystic fibrosis to endoplasmic reticulum stress: Differential role of Grp78 and ATF6","volume":"1772","author":"Kerbiriou","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jcf.2026.06.005_bib0041","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.3390\/cells10112980","article-title":"The interplay between the unfolded protein response, inflammation and infection in cystic fibrosis","volume":"10","author":"Trouv\u00e9","year":"2021","journal-title":"Cells"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:54:44Z","timestamp":1782939284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"alternative-id":["S1569199326016462"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPL84 and Trikafta\u00ae exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C\u2192T\/F508del CFTR variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}